Showing 81 - 100 results of 2,858 for search '"subgroup"', query time: 0.06s Refine Results
  1. 81
  2. 82
  3. 83

    Association of coronary revascularisation after physician-referred non-invasive diagnostic imaging tests with outcomes in patients with suspected coronary artery disease: a post hoc subgroup analysis by Takao Kato, Moriaki Inoko, Naoya Matsumoto, Yukari Uemura, Masanao Naya, Mitsuru Momose, Satoshi Hida, Takao Yamauchi, Takatomo Nakajima, Eriko Suzuki, Tohru Shiga, Nagara Tamaki

    Published 2020-09-01
    “…Objective We aimed to evaluate the association of the prognostic impact of coronary revascularisation with physician-referred non-invasive diagnostic imaging tests (single photon emission CT (SPECT) vs coronary CT angiography) for coronary artery disease.Design A post hoc analysis of a subgroup from the patient cohort recruited for the Japanese Coronary-Angiography or Myocardial Imaging for Angina Pectoris Study.Setting Multiple centres in Japan.Participants From the data of 2780 patients with stable angina, enrolled prospectively between January 2006 and March 2008 in Japan, who had undergone physician-referred non-invasive imaging tests, 1205 patients with SPECT as an initial strategy and 625 with CT as an initial strategy were analysed. …”
    Get full text
    Article
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88

    Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis by Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, Atsushi Mizokami, Hiroaki Kikukawa, Takeo Kosaka, Kazuo Nishimura, Motonobu Nakamura, Kazuki Kobayashi, Atsushi Komaru, Yuko Mori, Shigeyuki Toyoizumi, Natsuki Hori, Yoshiko Umeyama, Hirotsugu Uemura

    Published 2025-01-01
    “…Talazoparib Ctrough was comparable across Japanese, Asian, and non‐Asian subgroups. Conclusions In this exploratory analysis, efficacy outcomes with talazoparib plus enzalutamide in Japanese patients in TALAPRO‐2 were consistent with those in the overall all‐comers population. …”
    Get full text
    Article
  9. 89
  10. 90
  11. 91
  12. 92

    Efficacy of Single-Pill Combination of Telmisartan 80 mg and Hydrochlorothiazide 25 mg in Patients with Cardiovascular Disease Risk Factors: A Prospective Subgroup Analysis of a Randomized, Double-Blind, and Controlled Trial by Harold Bays, Pingjin Gao, Birgit Völker, Michaela Mattheus, Luis M. Ruilope, Dingliang Zhu

    Published 2013-01-01
    “…Report of prespecified and post hoc subgroup analyses of a randomized, controlled trial comparing telmisartan 80 mg/hydrochlorothiazide 25 mg (T80/H25) combination therapy with T80 monotherapy, according to the presence of cardiovascular disease (CVD) risk factors. …”
    Get full text
    Article
  13. 93
  14. 94

    Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of gastrointestinal bleeding: A cohort study based on the French National Health Data System (SNDS). by Gregory Y H Lip, Robert Benamouzig, Anne-Céline Martin, Giancarlo Pesce, Gaelle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Fouad Sedjelmaci, Jose Chaves, Rupesh Subash, Ruth Mokgokong

    Published 2025-01-01
    “…<h4>Results</h4>A total of 314,184 patients were identified; characteristics were similar for propensity score-matched subgroups in VKA/DOAC and DOAC/DOAC comparisons. DOACs showed lower risk of major bleeding versus VKAs in all subgroups evaluated (p<0.0001 for all). …”
    Get full text
    Article
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100